SPRY
ARS Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
consensus rating "Strong Buy"
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About SPRY
Ars Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing innovative treatments for severe allergic reactions
11682 El Camino Real, Suite 120, San Diego, California 92130
--
ARS Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on January 4, 2016. The company is a biopharmaceutical company focused on developing novel, potentially best-in-class product candidates, neffy for the emergency treatment of type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail that allows neffy to deliver injection-like epinephrine absorption in small doses, easy to carry, easy to use, fast to administer and reliable nasal sprays.
Company Financials
EPS
SPRY has released its 2024 Q4 earnings. EPS was reported at 0.48, versus the expected -0.12, beating expectations. The chart below visualizes how SPRY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
SPRY has released its 2024 Q4 earnings report, with revenue of 86.58M, reflecting a YoY change of NaN%, and net profit of 49.93M, showing a YoY change of 796.62%. The Sankey diagram below clearly presents SPRY’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
